2024 Video Webinar Series

The 340B Drug Pricing Program: Trends, Controversies, and Outlook (REPLAY)

Dr. Adam J. Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels, invites you to join him for DCI’s video webinar:

The 340B Drug Pricing Program:
Trends, Controversies, and Outlook
This event was broadcast live on Friday, June 21, 2024

This page describes the event and explains how to purchase a registration to watch the replay. Jump to pricing options. The webinar was broadcast from the Drug Channels studio in beautiful downtown Philadelphia.

This event is part of The Drug Channels 2024 Video Webinar Series.

WHAT YOU WILL LEARN

The federal 340B Drug Pricing Program continues to grow much more quickly than the overall pharmaceutical market. For 2023, total purchases under the 340B program exceeded $124 billion. DCI estimates that 340B discounts equated to more than 17% of total value of gross-to-net reductions for brand-name pharmaceuticals. The 340B program also remains a significant and controversial source of profits for the pharmacy and pharmacy benefit management (PBM) industries.

In this all-new webinar, Dr. Fein provided a fact-based look at the 340B program, summarized the multiple controversies surrounding the program’s operations, and delivered a clear-eyed outlook for the program’s future. Key topics included:

  • Current operations of the 340B program
  • 340B growth trends by dispensing/administration channel and covered entity type
  • Following the 340B dollar
  • Contract pharmacy controversies
  • PBM and pharmacy profits from the 340B program
  • Impact of CMS’s latest 340B guidance for the Inflation Reduction Act
  • The Coming HRSA vs. CMS Oversight Crisis
  • Manufacturers’ 340B strategies
  • How the IRA will affect 340B profits in Medicare Part B
  • State and federal legislative actions and outlook
  • And much more!

PLUS: During the webinar, Dr. Fein gave participants an opportunity to unmute themselves and ask live questions.

As always, Dr. Fein clearly distinguished his opinions and interpretations from the objective facts and data. He also drew from exclusive information found in DCI’s 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers.

Read on for full details on pricing and registration.

PRICING OPTIONS

You can register for this unique educational opportunity for only $400 per viewing device. Within one business day of your purchase, you will receive an email from Zoom with a unique link to access the event.

We are offering substantial discounts for multiple registrations from the same organization. We know that many of you are now working remotely, so rates for multiple registrations are as low as $280 per device—a 30% savings. An unlimited number of people may watch at one physical location if they can watch from a single device. Please note that a device at a single physical location may not record, stream, share, or project our webinar to other sites, devices, or locations. Each device at a physical location requires its own registration.

Click here to order. All discounts will be automatically computed based on the number of registrations you enter in your cart. (You can reset the cart by entering 0 in the quantity field.)

The 340B Drug Pricing Program: Trends, Controversies, and Outlook (REPLAY)ORDER

(You can reset the cart by entering 0 in the quantity field.)

Please contact Paula Fein (paula@drugchannels.net) if you have any questions. If you purchase access for multiple devices, we will contact you for a list of your participants and their email addresses. Or, download this spreadsheet and email your registrants’ information to dcisupport@hmpglobal.com.

Payment can be made with all major credit cards (Visa, MasterCard, American Express, and Discover) or via PayPal. Click here to email us if you would like to pay by corporate purchase order or check.

IMPORTANT THINGS TO KNOW

  • Watch and listen via any device with a web browser (computer, iPad, iPhone/Android, etc.) There is no access via telephone.
  • We use Zoom technology for this webinar. Every registrant will receive an email from Zoom with a link to watch the replay. This link is unique to the registrant and can only be accessed once. We recommend that every registrant download the Zoom client software/app.
  • Every registrant will receive an email from Zoom with links to download Dr. Fein’s slides.
  • This event is part of The Drug Channels 2024 Video Webinar Series. If you already purchased access to the 2024 Drug Channels Video Webinar Series, then you should have received an email from Zoom with a link to access the June 21 event.
  • Organizations that purchased corporate access for The Drug Channels 2024 Video Webinar Series will receive a custom, branded signup link so employees can easily register. We will automatically refund payments from anyone at a company with corporate access who purchases a single registration using their corporate email account.
  • Each registration for a DCI webinar is valid for a single device at a single physical location. Each device at a physical location requires its own registration. Attendees are not permitted to record, stream, share, or project a DCI webinar to other sites or locations. Purchasers who violate this limitation by recording, streaming, sharing, or projecting a DCI webinar to other sites, devices, or locations will be liable for the full cost of all locations that viewed the webinar. DCI reserves the right to prohibit purchasers who violate our terms from attending future DCI webinars.
  • Unfortunately, we are unable to offer refunds.